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Summary 
Human papillomavirus (HPV) testing has been shown to be far more sensitive and robust in 
detecting CIN2+ (and CIN3+) for cervical screening than approaches based on either cytology or 
visual inspection, but there are a number of issues that need to be overcome if it is to substantially 
reduce the morbidity and mortality from cervical cancer at a population level. The two main issues 
are coverage (increasing the numbers of women who participate in screening) and management of 
women who test high-risk HPV (hrHPV) positive. This article will review the potential for vaginal self-
collection to improve coverage and the options for triage of hrHPV-positive women in high-resource 
and low-resource settings.  
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Executive Summary 
HPV Testing 
• High risk HPV(hrHPV) infection is needed for cervical cancer to develop and since hrHPV DNA is still present 
during the development of cancer, looking for hrHPV DNA should be a good approach to identifying 
women with high-grade CIN.  
• The advantages of hrHPV testing over cytology (currently the most widely used screening method) are that 
HPV negative women are extremely unlikely to develop cervical cancer over the next  5-10 years and 
infrequent screening would be safe. Additionally HPV testing does not depend on collection of samples 
with good morphology.    
• Screening for cervical cancer using HPV testing is more sensitive than screening using cytology but 
considerably less specific. A greater proportion of women will test HPV positive on a single screen 
compared to the proportion found to have abnormal cytology. Therefore a good way of managing HPV 
positive women is essential. 
Management of women positive for HPV  
• A positive HPV test in primary screening should only trigger a triage test not automatic referral to 
colposcopy. The most widely studied triage test in this situation is cytology. Triage with cytology can be 
done on the same sample as the HPV test without the need for women to attend for another clinic visit. 
• HPV positive women with normal cytology need not be retested at a short interval, but neither should they 
be re-screened only every 3 or 5 years. A repeat test after an interval of 12-24 months seems reasonable. 
• Genotyping for HPV 16 and 18 has been proposed as a good alternative for women who test HPV positive 
and cytology negative because the risk of CIN3+ is genotype dependent and HPV types 16 or 18 are found 
in over 70% of cervical cancer. However being HPV positive, but negative to HPV16 and 18 confers an 
increased risk of cervical disease and these women cannot be returned to routine screening. 
• One particularly promising triage test is the immunocytochemical detection of over-expression of the 
p16INK4a tumour suppressor gene as a surrogate marker for the transforming activity of hrHPV onco-
proteins that are essential for the initiation and maintenance of the neoplastic process. Currently the 
potential of this test is limited by the lack of standardised reporting and a need for substantial expert 
interpretation.  
• DNA methylation of a panel of both human and HPV gene markers to be used as triage tests is an exciting 
area of current research. 
Vaginal self-collection for HPV-testing 
• Testing for HPV in vaginal self-collected samples offers a relatively cheap and effective way of improving 
cervical screening coverage in many settings. 
• The performance of the HPV test on self collected samples, in terms of clinical sensitivity and specificity for 
CIN2+ in the screening setting, is not as good as HPV testing on clinician-taken cervical specimens; in most 
studies the sensitivity or specificity are quite variable, showing values between 60 to 90%. However it is 
fairly clear that HPV testing on self collected samples is as sensitive and sometimes more sensitive than 
developed-country cytology-based screening of cervical specimens; however, cytology is the more specific 
test. 
Conclusions 
• HPV testing is the preferred approach to primary cervical screening in both high and low-resource settings.  
• The best well-validated option for triage of HPV positive women is cytology. Genotyping for HPV16 and 
some other HPV types or alternatively p16 alone or p16 in combination with Ki-67 are also currently under 
evaluation as possible triage options for high risk HPV positive women.  
• Testing for HPV in vaginal self-collected samples offers a relatively cheap and effective way of improving 
cervical screening coverage in many settings.  
• In the future DNA methylation may provide a suitable triage assay for vaginal self-collected samples. 
 
  
Background 
Cervical screening works by detecting and treating high grade cervical intraepithelial neoplasia (CIN), 
typically CIN2 and above (CIN2+) or in some settings CIN3 and above (CIN3+). In the absence of 
treatment some, but not all, CIN3 would progress to cervical cancer.[1, 2] Cervical cancer is rare in 
women previously adequately treated for CIN.[3, 4]  
For many years cervical screening was done by (conventional) cytology: a sample was collected using 
a spatula and smeared onto a glass slide before being analysed under a microscope in a laboratory. 
Today many screening programmes use liquid based cytology (LBC) instead: samples are now 
collected using a small plastic broom and stored in a liquid transport medium. Glass slides are 
prepared from the cells in this transport medium in the laboratory. LBC is considered to be better 
than conventional cytology in that it is easier and quicker to see what is on the slide, but research 
studies have not shown that it is better than conventional cytology at detecting high-grade CIN.[5] 
The success of effective screening programmes stem from their good coverage (eg in the UK around 
80% of the target population has been screened in the last five years) and the high-level of quality 
assurance. Cervical cytology depends on the collection of good samples and the skilled 
interpretation of cells under the microscope. Both activities require extensive training and 
continuous quality assurance. Examining cells under a microscope is a skilled job that relies on 
concentration (not to miss something) and human judgement to interpret what is seen. Cervical 
screening has been ineffective in most low-resource countries because of an inability to obtain high 
coverage with a reliable screening test. 
Cervical cancer is caused by around 15 high risk types of the human papilloma virus (hrHPV), notably 
types 16 and 18 which together give rise to about 70% of all cases. Although infection of the cervix 
with HPV is very common, there would be no (or virtually no) cervical cancer without HPV 
infection.[6] In most cases, the body’s immune system clears a cervical HPV infection within a year 
  
or two.[7] hrHPV infection may lead to high grade CIN and high grade CIN sometimes progresses to 
cervical cancer. The time from hrHPV infection to cancer (in women developing cancer) varies 
hugely, but it is very rare for cancer to develop in less than 7 years and it is not uncommon for 
cancer to develop more than 30 years after infection. 
HPV testing 
Since hrHPV infection is needed for cancer to develop and since hrHPV DNA is still present during the 
development of cancer, looking for hrHPV DNA should be a good approach to identifying women 
with high-grade CIN. Additionally, since the time from hrHPV infection to cancer is long, a woman 
who is HPV negative is extremely unlikely to develop cervical cancer over the next 5-10 years and 
infrequent screening would be safe. Thus, there are two potential uses for HPV testing: (i) to identify 
those likely to have disease now (and would benefit from treatment); and (ii) to identify those who 
might develop disease in the next few years (or by elimination those who are extremely unlikely to 
develop disease over the next several years and therefore do not need to be screened again for 
several years). However, any HPV assay used for screening purposes will need to be clinically 
validated for the detection of CIN2+. Most commercial HPV tests are based on DNA but two are 
based on RNA. One of these tests is restricted to five HPV types and has lower sensitivity and the 
other has similar sensitivity to the DNA based test.[8] 
There have been many studies comparing HPV testing to cytology for the detection of high grade 
CIN. All large studies have found that HPV testing is at least as good as cytology at detecting high-
grade CIN and most studies find HPV testing to be better (ie, it is more sensitive).[9-12] The 
disadvantage of HPV testing is that it is less specific than cytology. That is, among women without 
high grade CIN more will test positive for HPV than will have abnormal cytology. 
Another advantage of HPV testing is that it does not depend on the preservation of good quality 
morphology.  In stark contrast to cytology, reasonable results can be obtained by using HPV testing 
  
on samples that women collect themselves. [13] Further, HPV testing does not rely on human 
judgement and the results are reproducible in different laboratories. In studies comparing cytology 
to HPV testing in Europe and North America[11], the sensitivity of cytology varied from less than 
40% to about 80% (average 53%) whereas the sensitivity of clinician-based HPV testing was 
consistently above 85% (average 96%). The specificity of both tests increased with age, however 
cytology was on average more specific (96%) than HPV testing (91%). 
Longitudinal studies show that the rate of high-grade CIN after a negative HPV test is considerably 
less than the rate after negative cytology.[14-17] In a joint European study the cumulative risk of 
CIN3+ six years after a negative HPV test was significantly less (0.27%) than the cumulative risk three 
years after a negative cytology (0.51%).[14] One study of cervical cancer incidence in the five years 
following screening with both cytology and HPV testing reported half the rate of cervical cancer 
following a negative HPV test compared to following a negative cytology test.[18] 
Randomised controlled trials (RCTs) have shown that the additional cases of high-grade CIN picked 
up by HPV testing but missed by cytology are not simply indolent disease that would not have 
progressed to cancer in the short term.  In all four  RCTs of cytology versus HPV testing within 
established screening programmes with published results for the second round of screening, the 
rate of high-grade CIN detected at round two (i.e. between one and  five years after enrolment) was 
substantially lower (approximately half) in those individuals originally screened by HPV testing 
compared to those originally tested by cytology alone.[19-22] Thus by treating more disease in the 
first round, the trials found that there was less detected in the second round. Further, the limited 
data on the incidence of cervical cancer in RCTs suggest that HPV testing does indeed result in fewer 
cases of cervical cancer on follow-up. In the Italian trial [22]  there were 9 cancers in the cytology 
arm compared to 0 in the HPV arm after the initial screen and in the Dutch [21] trial there were 14 
versus 4. Results in the Swedish trial[20] including those detected at first screen, found five 
squamous cell carcinomas in the cytology arm and one in the HPV arm.  
  
Initially, many people believed that HPV testing was too expensive to be used in middle and low-
income countries and that cytology or simply looking at the cervix would be adequate to greatly 
reduce the burden of cervical cancer. There was much interest in visual inspection after application 
of dilute acetic acid (VIA). Indeed for many years VIA was the favoured approach of the Alliance for 
Cervical Cancer Prevention; one of the main organizations working to prevent cervical cancer in 
developing countries. However, a trial in the San Martin region of Peru that compared conventional 
cytology, VIA and HPV testing to screen over 5000 women found that the sensitivity of HPV testing 
was far superior to that of cytology and VIA, and that the specificity of VIA was considerably 
lower.[23]   Further a cluster randomised trial in India, reported –“34 deaths from cervical cancer in 
the HPV-testing group, compared with 64 in the control group (hazard ratio, 0.52; 95% CI, 0.33 to 
0.83). No significant reductions in the numbers of advanced cancers or deaths were observed in 
either the cytology group or the VIA group, as compared with the control group”.[24]  
Management of women positive for HPV 
The great advantage of HPV testing for most women is that HPV negative women can have their 
screening interval extended to over 3 years.[14] By extending the screening interval to six or even 10 
years, the proportion of women who will test positive on at least one HPV screen by age 65 will be 
similar to the proportion that test positive on at least one cytology screen in current programmes. 
Since the rate of disease following an abnormal HPV test is half the rate of disease following an 
abnormal cytology, where screening interval is 5 years, extending the screening interval to 10 years 
should roughly result in the same number of women testing positive as they currently do.  
The greater proportion of women testing HPV positive on a single screen (compared to the 
proportion with abnormal cytology) need not be a problem as demonstrated by the very large trials 
of primary HPV testing that have been run successfully in several countries (including England). The 
first solution is good management of HPV positive women. A positive HPV test in primary screening 
  
should only trigger a triage test not automatic referral to colposcopy. The most widely studied triage 
test in this situation is cytology. Triage with cytology can be done on the same sample as the HPV 
test without the need for women to attend for another clinic visit (when the sample is taken using 
liquid based cytology transport medium). Effectively the same women (those positive on both 
cytology and HPV testing) are immediately referred to colposcopy regardless of whether one screens 
using cytology triaged by HPV testing or HPV testing triaged by cytology.[25] In practice, because 
cytology is subjective, more women may be considered morphologically abnormal when they are 
known to be HPV positive. Evidence of this was observed in the Finish trial[12], where women were 
referred to colposcopy based in their cytology result, in particular women under age 35. Introduction 
of primary HPV testing should be closely monitored to assess whether the increase in 
morphologically abnormal cytology is associated with the learning curve or whether it will affect 
referral rates long term Conversely, a very small number of women who would be referred to 
colposcopy with high-grade cytology, without HPV triage, will test negative for HPV and will not have 
cytology triage. HPV positive women with normal cytology will be re-screened at a shorter interval 
(e.g. every 12 months). In this way the sensitivity of HPV testing will be maintained but the numbers 
referred to colposcopy need not be excessively increased.  
Current proposed strategies to deal with HPV positive/cytology negative women suggest they should 
be retested 12-24 months later (with HPV and cytology). Women who are still HPV positive or those 
that develop cytological abnormalities upon retesting are referred  to colposcopy .[26-28] Support 
for this strategy comes from cohort study evidence that suggest 90% of HPV infections will be self 
clearing in a period of 1 to 2 years.[15, 16] Nevertheless referring all women who test HPV 
positive/cytology negative twice 12 months apart leads to higher colposcopy referral rates than 
those observed in cytology screening programmes.  
  
Genotyping for HPV 16 and 18 
Genotyping for HPV 16 and 18 has been proposed as a good alternative for women who test HPV 
positive/cytology negative because the risk of CIN3+ is genotype dependent[25, 29, 30] and HPV 
types 16 or 18 are found in over 70% of cervical cancer.[31] HPV 16 ( but not HPV18) is associated 
with a high cross-sectional rate of CIN2+ and CIN3+.[8] Women with HPV 18 and HPV 45 are more 
likely to develop disease (particularly adenocarcinomas in the endocervical canal) than are women 
with other high risk types.[31, 32] The risk of CIN3 reaches 10% over one to four years for HPV16 
positivity and over 2 to 5 years for HPV18 positivity.[30, 33] By contrast the 12 months risk of CIN3+ 
after a HPV positive/cytology negative test ranges from 0.8% to 4.1%.[26]  
Studies have shown that HPV DNA testing followed by triaging with cytology and screening for 
persistent HPV type-specific infection (genotyping) has a considerably higher sensitivity for detecting 
CIN3+ than screening by cytology alone with a modest increase in screening tests and referrals.[25, 
28]  These results have been validated as part of the ATHENA trial[9] in a scenario where HPV is the 
primary test. Being hrHPV positive but negative to HPV16/18 carries an increased risk of CIN3 in the 
next two years of 2.9%.[21] For this reason the lack of HPV16/18 cannot be used to return women to 
routine screening.  
Genotyping for triage has been primarily investigated in women over the age of 30. In younger 
women, the proportion testing HPV16/18 positive may be too high to justify referring them all; 
however, the proportion of CIN3+ harbouring HPV16 also decreases in older women, indicating the 
need for careful follow-up of hrHPV women regardless of HPV type.[9]  
Immunocytohemical detection of p16INK4a  
Triage using other biomarkers has been less comprehensively evaluated. One particularly promising 
test is the immunocytochemical detection of over-expression of the p16INK4a tumour suppressor gene 
as a surrogate marker for the transforming activity of hrHPV onco-proteins that are essential for the 
  
initiation and maintenance of the neoplastic process. A number of studies looking at p16INK4a staining 
of cervical cytology showed that women with CIN1 positive for p16 were more likely to be 
subsequently diagnosed with CIN2+ .[34-36] Unfortunately the sensitivity of p16 varies hugely in the 
literature due to difficulties in reading the slides, lack of standardised reporting and a need for 
substantial expert interpretation. In general p16 is less sensitive for CIN2+ or CIN3+ than is HPV 
testing, but most studies have found it to be more specific at identifying women with high-grade 
disease.[8, 37-39]  
A more recent development has been double staining for p16INK4a and ki-67. Several studies 
investigating the performance of the paired markers p16INK4a/ki-67 found that the results were quite 
similar to p16INK4a alone.  The main difference between the single and the paired markers is that 
p16INK4a should be read by an expert and requires considerable interpretative skills to rule out false 
positives due to staining of endocervical and other cells. In contrast the p16INK4a/ki-67 marker pair is 
read differently and can be more easily interpreted correctly by a less experienced 
cytopathologist.[38, 40-42] A study by Carozzi F et al [38] is of particular interest since good results 
on p16INK4a were demonstrated in women aged 25-34, showing that p16INK4a may be considered as a 
triage marker for these hrHPV -positive women. A recent paper from the same study with additional 
follow-up showed that p16INK4a positivity in hrHPV-positive women had a cumulative 3 year absolute 
risk for CIN2+ of 19.5% with a longitudinal sensitivity of 75.6%.[43] The data suggest that p16INK4a 
may be considered as an option for triage of hrHPV- positive women  
DNA Methylation 
DNA methylation (DNAme) of host cell DNA has been proposed as an alternative triage for hrHPV-
positive women because DNAme plays an essential role in gene transcription and in genomic 
stability. Aberrant methylation leads to cell immortality and malignant transformation.[44]  The use 
of DNAme for triage would have the advantage of being an automated, objective test that could be 
run on the same sample as the HPV assay. 
  
Of the more than 50 human genes tested so far in cervical tissue, [45]  15 have been reported in five 
or more studies and three genes (CADM1, DAPK1 and RARB) have been repeatedly shown to have 
elevated methylation in cervical cancers. . Hesselink et al[46] evaluated CAD1/MAL methylation to 
triage HPV positive women in a large population-based screening study. They found it to be as 
effective at detecting CIN3+ in HPV positive women as cytology with HPV16/18 genotyping. Studies 
of host cell methylation use different clinical specimens, methylation assays, assay thresholds and/or 
selected promoter regions making consistency among results difficult .[44] 
The methylation of HPV genes, especially HPV16, in disease progression has been a major focus of 
research. Elevated methylation of the HPV 16 L1 and L2 open reading frames (ORF) in particular is 
associated with high grade CIN and invasive cancer.[47-49]  Recently the association between 
specific patterns of DNAme in HPV16 L1 and L2 and high-grade CIN has been validated in a small 
prospective study.[50] Further validation in large studies is required. The potential utility of 
methylation of other regions of the HPV16 genome as a biomarker for CIN2+ is less clear because 
studies have been small and the results were highly variable. To expand the potential utility of 
HPV16 methylation assays for predicting risk of cancer additional research needs to be directed to 
other HPV types such as 18, 31, 33 and 45. 
DNAme of a panel of both human and HPV gene markers is an exciting area of current research. 
Vaginal self-collection for HPV testing 
For years conventional cervical screening has relied on clinician-collected cervical specimens, 
however, vaginal self-collection for HPV testing is likely to become an integral part of screening in 
both the developed and developing world. This is because self collection has the potential to 
overcome two major problems inherent in current screening strategies: cost and coverage. It is 
difficult to maintain the large numbers of clinics required for mass population screening, especially 
in resource-constrained regions. Even in countries that manage to do this well, 80% compliance with 
  
the recommended screening intervals is considered extremely good. Women who are not screened 
or attend infrequently are at highest risk of developing cervical cancer.[51] Studies have shown that 
self collection for HPV testing is a practical and effective way to collect exfoliated cell specimens 
from the vaginal tract and cervix that is broadly acceptable to women [52-55]  and eliminates the 
cost of visiting a clinician.   
Acceptability of vaginal self collection 
Numerous studies in a wide variety of countries and ethnic groups over the past decade have 
reported that self collection is well-accepted by women and in some more educated groups may be 
preferred to speculum-based cervical sampling. [56-61] Virtually all measures of acceptability, 
including pain, embarrassment and anxiety favour the self collection approach. However, a 
consistent negative theme across the studies is that 50 to 70% of women worry they will not take 
the sample properly.[56-58, 62] This is actually a misconception, it is easy for a woman to take a self 
collected sample correctly and the samples are almost always good. There do not appear to be any 
specific cultural or religious barriers to self-sampling,[62, 63] although one study in the UK found 
that Muslim women were reluctant to use the self collection approach.[52]  
The main problem in high-income countries with well-established screening programmes is low 
coverage and falling participation rates.  A well-recognised barrier to cervical screening attendance is 
the need to undergo a pelvic examination, which some women find to be uncomfortable, invasive or 
unacceptable (for emotional or cultural reasons).[54] However, practical barriers may be more 
predictive of non-attendance behaviour.[64] The self collection approach allows the women to 
obtain samples in privacy and comfort with the additional benefit of being able to choose the time 
and place of sampling.  
The devices most commonly used for self collection are swabs, which may be made of spun 
polyester fibre or treated cotton on a plastic shaft or special flocked swabs with a somewhat rough 
surface; untreated cotton swabs should not be used. Another device is a small soft nylon brush 
  
similar in shape to an artist’s brush but with much wider diameter bristles (Rovers® Viba-Brush) or a 
small soft nylon brush similar to a Christmas tree-shaped mascara brush. Yet other approaches use 
plunger-like devices (Delphi device) to do a vaginal lavage. Women may be reluctant to use devices 
that look uncomfortable or appear like medical implements; to some extent even simple swabs may 
be resisted by some women. There are now several companies focused on delivering elegant self 
collection devices, with a look and feel that is more attractive to feminine sensibilities (for example, 
the Evalyn sampler, Rovers Medical). While such devices may cost more they may be more 
acceptable, more readily used and returned at higher rates to the clinicians, thus promoting greater 
compliance with screening and saving costs in the long run.   
Sensitivity and specificity of vaginal self sampling 
Overall, the reviews which compared self collection versus clinician-collected samples found 
comparable values for HPV prevalence , [65-67] although self collection may detect more low risk 
HPV types.[65, 68] The performance of the HPV test on self collected sample, in terms of clinical 
sensitivity and specificity for CIN2+ in the screening setting, is not as good as HPV testing on 
clinician-taken cervical specimens. Of the 10 studies comparing self collected samples vs. clinician 
collected samples reported by Snijders et al[13]  nine found the clinician collected sample to be 
more sensitive and one found it to be as sensitive. In most studies the sensitivity or specificity of self 
collected samples are quite variable, showing values between 60 to 90%.[13] Best results, in terms 
of clinical sensitivity and specificity, depend on the combination of the sampler, transport conditions 
(medium and conduits) and the assay. Clinical validation of a combination, rather than just its 
individual components, should be required before it is used in routine practice[13] 
It is fairly clear that HPV testing on self collected samples is as sensitive and sometimes more 
sensitive than developed-country cytology-based screening of cervical specimens; however, cytology 
is the more specific test.[13] In contrast, in resource constrained regions where routine cytology is 
often quite poor, HPV testing on self collected samples is usually more sensitive than cytology-based 
screening. A large randomized clinical trial in Mexico[69] and several smaller observational studies in 
  
China[70] have shown that HPV testing of self collected specimens is a much more sensitive 
approach than local routine cytology screening and may address issues related to the lack of access 
of poor women to screening. The study by Lazcano et al[69] in Morelos State Mexico randomized 
25,061 women living in 540 poor communities to either routine clinic-based cytology or self 
collection in their homes followed by HPV testing, women positive on either test were referred to 
routine colposcopy and biopsy of any abnormal areas of the cervix. Among the 11,054 participants 
of the cytology arm there were 38 CIN 2+ discovered of which 8 were invasive cancers, while among 
the 9,292 participants in the HPV arm there were 108 CIN2+ detected of which 28 were cancers; 
overall 3.4 (95% CI=2.4-4.9) times more high grade CIN was detected by HPV testing on self collected 
samples than by routine cytology. A report from China[70] presents a pooled analysis of the 
diagnostic accuracy of self collection in five small to medium population-based studies of mostly 
poor rural women. The studies had a colposcopy reference standard with biopsy as appropriate on 
women positive by any screening test, including liquid based cytology, visual inspection by acetic 
acid, self collection and physician-based cervical HPV testing, using the same HPV assay as in Mexico. 
Of 13,004 women in the pooled analysis 507 were diagnosed with CIN2+. Self collection with HPV 
testing had a sensitivity of 86.2% and a specificity of 80.7% as compared to a sensitivity of 97% and a 
specificity of 82.7% for physician-based HPV testing. Liquid based cytology was significantly less 
sensitive than either HPV test.  
Cervical screening using vaginal self-sampling for HPV testing 
Conventional cervical screening has never been successfully transferred to developing or low-income 
countries because of the need for infrastructure and the associated costs. Unsurprisingly, 85% of the 
global burden of cervical cancer arises from these areas.[71]  However, self collection is 
comparatively resource-efficient and has the potential to provide effective widely available 
screening to these largely unscreened populations. [69, 72, 73]  
  
Studies mainly in the Netherlands and Scandinavia have shown a way to implement self collection in 
developed countries that is complementary to current screening systems, regardless of whether the 
primary screening is based on cytology or HPV testing. The main problem in these countries is a lack 
of adherence to screening guidelines. Several studies have shown that offering self collection to non-
compliant women was superior to a recall invitation for cytology in attracting them to participate 
again in the screening program.[13, 58] Nine studies reporting response rates to self-sampling 
amongst non-attendees showed that between 8 and 39% of non-attendees of the cervical screening 
program provided self collection samples to the laboratory.[74-82] Giorgi et al[74] found a 
substantial decrease in participation among Italian women when self-sampling was available as an 
opt-in versus providing self collection devices directly to the non-attendees (8.7% versus 19.6%). An 
interesting study of self collection in the Netherlands[78] used the national postal service to deliver 
and return the devices. The research team studied 26,409 non-compliant women of whom 26,145 
were offered self collection while a control group of 264 women were offered a re-invitation to 
cytology. They found a 30.8% return of the self collection devices versus 6.5% of the control group 
who attended cytology screening.  Subsequently 89% of the HPV positive women took a triage 
cytology test, with 95.8% of those with abnormal cytology going to colposcopy. The rate of CIN2+ 
and invasive cancer discovered on colposcopy in the self collection group was 1.5% and 0.1% 
respectively, rates which are similar to those seen in the developing world. The next challenge for 
self collection in countries with an established screening programme will be to see if the increased 
coverage observed in research settings will translate into population screening. Achieving high rates 
of women attending triage following an HPV positive self-sampling test (reflex cytology is not 
possible from the self-sample) presents a particular challenge. This is why a molecular test (such as 
DNA methylation or genotyping) from the self-collected sample is attractive because it can be done 
without requesting another sample or an examination from the woman. Currently the only 
commercially available molecular triage is genotyping for HPV16 and perhaps HPV18, although the 
  
latter has questionable specificity, however in the future methylation may provide a suitable triage 
assay for vaginal self-collected samples. 
Overall the studies support the use of self collection to improve cervical cancer prevention in non-
compliant and poor women worldwide. It appears that the next logical step is large-scale pilot 
implementation of HPV testing on self collected samples in developed countries, as well as in 
resource-constrained regions and poor countries that have sufficient economic capacity and 
provider skills with appropriate infrastructure. Prior to implementation there should be a thoughtful 
analysis of the program including: 1) the screening groups and means of contact, 2) the primary 
testing and triage approach, 3) rendering of accurate final diagnoses, 4) treatment, follow-up and 
documentation.  
Conclusions 
HPV testing is seen to be the preferred approach to primary cervical screening in both high and low-
resource settings.[83] Testing for HPV in vaginal self-collected samples offers a relatively cheap and 
effective way of improving cervical screening coverage in many settings. Currently the best well-
validated option for triage of HPV positive women is cytology, but that requires a clinician-collected 
sample from the cervix. Genotyping for HPV16 and some other HPV types or alternatively p16 alone 
or p16 in combination with Ki-67 are also currently under evaluation as possible triage options for 
hrHPV positive women. In the future DNA methylation may provide a suitable triage assay for 
vaginal self-collected samples. Even with affordable HPV testing, middle and low income countries 
will have to overcome the infrastructure challenges needed to ensure good follow-up, triage and 
treatment of HPV positive women. 
  
Future Perspectives 
HPV co-testing has become the predominant method of screening in the United States. Eventually 
HPV testing is likely to become the primary screen in the USA with cytology used as the triage test on 
hrHPV positive women. In the next 5 to 10 years HPV testing will be introduced as the primary 
screening test in organised screening programmes in many countries in Europe.  HPV screening in 
Asia and Latin America is also taking hold, there will be a diversity of tests and approaches and in 
general adoption will be quite slow and be region specific. Triage of HPV positive women, using 
various combinations of genotyping, immunochemistry and molecular markers, will begin to be 
introduced as part of some population based screening programmes. Vaginal self-collection will be 
used to boost coverage wherever HPV testing is used.   
The impact of HPV vaccination on women of HPV screening age (those over age 30) is still 5 to 10 
years away and more data on the population-based efficacy of the vaccine for preventing cervical 
cancer will be needed before recommendations on altering current screening algorithms can be 
made. Rational algorithms will distinguish between women known to have been vaccinated (3 
doses) whilst under age 15 years and those not known to have been vaccinated or known not to 
have been vaccinated against HPV 16 and 18. Nevertheless, a combination of HPV vaccination and 
HPV testing will be the cornerstone of cervical cancer control globally. 
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